Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin- resistant advanced breast cancer patients: A phase II study

Tumori

Volumn 85, Issue 6, 1999, Pages 478-482

  Šušnjar, Snežana ^a   Vasović, Suzana ^a   Nešković Konstantinović, Zora ^a   Stamatović, Ljiljana ^a   Lukić, Vesna ^a   Čolaković, Slobodanka ^a   Mitrović, Labuda ^a   Jelić, Svetislav ^a   Radulović, Siniša ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Advanced disease; Anthracycline resistance; Breast cancer; Second line mitoxantrone chemotherapy

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; PHASE 2 CLINICAL TRIAL;

EID: 0342948816     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500610     Document Type: Article

References (22)

1. Bascioni R., Giorgi F., Silva R.R., Acito L., Giustini L., De Signoribus G., Giuliodori L., Testa E.: Mitoxantrone, fluorouracil and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. Breast Cancer Res. Treat., 45: 205-210, 1997.
2. Bonadonna G., Gianni L., Santoro A., Bonfante V., Bidoli P., Casali P., Demicheli R., Valagussa P.: Drugs ten years later: Epirubicin. Ann. Oncol., 4: 359-369, 1993.
3. Clemons M., Leahy M., Valle J., Jayson G., Ranson M., Hayes S., Howell A.: Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Eur. J. Cancer. 33: 2171-2182, 1997.
4. Colozza M., Gori S., Mosconi A. M., Anastasi P., Basurto C., Ludovini V., De Angelis V., Giansanti M., Tonato M.: Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil and L-leucovorin. Breast Cancer Res. Treat., 38: 277-282, 1996.
5. Doroshow J.H., Leong L., Margolin K., Flanagan B., Goldberg D., Bertrand M., Akman S., Carr B., Odujinrin O., Newman E.: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J. Clin. Oncol., 7: 439-444, 1989.
6. Durr FE.: The preclinical rationale for the use of mitoxantrone in primary medical therapy. In: Pharmanual: Mitoxantrone in the Treatment of Early Breast Cancer Bonadonna G. (Ed.), pp. 11-27, PharmaLibri, Montreal, 1994.
7. Gianni E.: Anthracycline resistance: the problem and its current definition. Semin. Oncol., 24 (suppl. 10): 11-17, 1997.
8. Hainsworth J.D., Andrews M.B., Johnson D.H., Greco F.A.: Mitoxantrone, fluorouracil and high-dose leucovorin: an effective, well-tolerated regimen of metastatic breast cancer. J. Clin. Oncol., 9: 1731-1736, 1991.
9. Haller D.: Calcium folinate: low dose or high dose. In: Adjuvant Therapy for Colorectal Cancer: What Next? Highlights from the 32nd Annual meeting of the ASCO, Philadelphia. PA, 18-21 May 1996. Inpharma weekly, suppl 4, 1996.
10. Hayward J.E., Carbone P.P., Heuson J.C., Kumaoka S., Segaloff A., Rubens R.D.: Assessment of response to therapy in advanced breast cancer. Cancer, 39: 1289-1294, 1977.
11. Henderson I.C.: Mitoxantrone for advanced breast cancer: comparison with other standard agents. In: Pharmanual: The Role of Mitoxantrone in Malignant Diseases, Mouridsen H.T., Arlin Z.A. (Eds.), pp. 49-66, PharmaLibri, New Jersey, 1987.
12. Ingle J.N., Kardinal C.G., Suman V.J., Veeder M.H., Schaefer P.L., Kirschling R.J., Mailliard J.A.: Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer. Breast Cancer Res. Treat., 43: 193-200, 1997.
13. Jones S.E., Mennel R.G., Brooks B., Westrick M.A., Allison M.A., Paulson R.S., Tilmann K., Rea B.: Phase II study of mitoxantrone, leucovorin and infusional fluorouracil for treatment of metastatic breast cancer. J. Clin. Oncol., 9: 1736-1739, 1991.
14. Lemmens J., Berteloot P., Thomas J., Wildiers J., Paridaens R.: Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. Eur. J. Cancer. 31A: 2114-2115, 1995.
15. Miller A.B., Hoogstraten B., Staquet M., Winkler A.: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
16. Minckwitz G.: Mitoxantrone vs FEC in high-risk metastatic breast cancer. Oncol. Rev., 12: 16, 1997.
17. Neidhard J.A., Gochnour D., Roach R., Hoth D., Young D.: A comparison of mitoxantrone and doxorubicin in breast cancer. J. Clin. Oncol., 4: 672-677, 1986.
18. Saletan S.: Mitoxantrone: an active, new antitumor agent with improved therapeutic index. Cancer Treat. Rev., 14: 297-303, 1987.
19. Simon R.: Optimal two-stages design for phase II clinical trials. Control. Clinical Trials, 10: 1-10, 1989.
20. Swain S.M., Lippman M.E., Egan E.F., Drake J.C., Steinberg S.M., Allegra C.J.: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7: 890-899, 1989.
21. Valero V.: Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin. Oncol., 24 (suppl. 13): 1311-1318, 1997.
22. Wils J.A.: Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: an effective regimen for the treatment of advanced breast cancer. Eur. J. Cancer. 29 A (15): 2106-2108, 1993.